UPTRAVI® (selexipag) Treatment Recommendations

UPTRAVI^® is the only prostacyclin pathway therapy recommended at first follow-up for intermediate–low-risk patients^*

Structured risk assessment should be conducted every 3 to 6 months for patients with PAH^†

UPTRAVI^® is the only prostacyclin pathway therapy to receive the highest class recommendation (Class I, Level B)^‡ for sequential triple- and dual‍-‍combination therapy

*The 2022 ESC/ERS Guidelines recommend adding UPTRAVI® for patients without cardiopulmonary comorbidities who are at intermediate-low risk despite receiving ERA/PDE5i therapy. In these patients, switching from a PDE5i to riociguat may be considered. In patients who present as intermediate-high or high risk on oral therapies, also consider adding UPTRAVI® or switching from a PDE5i to riociguat if it is not feasible to add IV or SC prostacyclin analogs.

^†Structured risk assessment should be conducted in cases of clinical worsening.

^‡Class I recommendation definition: evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. Level B evidence definition: data derived from a single randomized clinical trial or large nonrandomized studies.

Treat Early With UPTRAVI^®1

2022 ESC/ERS Guidelines Recommendations for UPTRAVI® (selexipag)²

Treat Early With UPTRAVI®1

2022 ESC/ERS Guidelines Recommendations for UPTRAVI® (selexipag)2

Treat Early With UPTRAVI^®1

2022 ESC/ERS Guidelines Recommendations for UPTRAVI® (selexipag)²